JAGSONPAL PHARMACEUTICALS LTD. SHARE PRICE [LIVE]

  
NSE: JAGSNPHARM
334.60
BSE: 507789
335.40
To view real time prices Login to your account
OPEN YOUR FREE DEMAT ACCOUNT AND START TRADING SEAMLESSLY
Already an existing customer? - Login Now!
NSE
BSE Click here to view BSE data
Live Chart
Loading, Please wait...
Error in Fetching Data, Please retry later.
No data available.
Open:
High:
Low:
MKT Cap:
52-wk High:
52-wk Low:
Prev close:
P/E:
Div yield:

Fundamental analysis

Quality

Valuation
0 250 500 750 1 000
Financial trend

What is not working for the company?

What is working for the company?

Stock
116.31%
Sector
-6.39%
Sensex
8.62%
Outperformed both Sector by 122.7% and Sensex by 107.69%
IndustryPharma
MARKET CAP (Micro Cap Stock)Rs 889 Cr
PE (TTM) 46.17
DIVIDEND YIELD 0.00%
PE Ratio46.17
Price to Book Value6.78
EV to EBIT34.70
EV to EBITDA32.78
EV to Capital Employed10.15
EV to Sales3.68
PEG Ratio0.00
Dividend YieldNA
ROCE (Latest)35.39%
ROE (Latest)14.67%
NameSep 22Jun 22
Promoters (Change:-0.00) 68.71%68.71%
FIIs (Change:0.00) 0%0%
Mutual Funds (Change:0.00) 0%0%
Insurance Companies (Change:0.00) 0%0%
Other DIIs (Change:-0.27) 0.41%0.68%
Non Institution (Change:0.26) 30.87%30.61%

Similar Stocks

Return Calculator

This tools helps you project your potential return on investments for the given stock, for a specified amount over a per-defined period of time.

If I had made LUMPSUM investment of ₹ 1,00,000

in JAGSONPAL PHARMACEUTICALS LTD.

Months ago

My investment would be worth ₹ 1,41,900 with a Gain of 41.90 %

JAGSNPHARM News

Frequently Asked Questions

What is the Share price of JAGSONPAL PHARMACEUTICALS LTD. (JAGSNPHARM)?

JAGSONPAL PHARMACEUTICALS LTD. (JAGSNPHARM) share price as of December 5, 2022, on NSE is Rs 334.60 (NSE) and Rs 335.40 (BSE) on BSE.

Can I buy JAGSONPAL PHARMACEUTICALS LTD. (JAGSNPHARM) shares?

Yes, You can buy JAGSONPAL PHARMACEUTICALS LTD. (JAGSNPHARM) shares by opening a Demat account with Angel One.

How do I buy JAGSONPAL PHARMACEUTICALS LTD. (JAGSNPHARM) from Angel One?

JAGSONPAL PHARMACEUTICALS LTD. (JAGSNPHARM) share can be brought through the following modes:
  1. Direct investment: You can buy JAGSONPAL PHARMACEUTICALS LTD. (JAGSNPHARM) shares by opening a Demat account with Angel One.
  2. Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to JAGSONPAL PHARMACEUTICALS LTD. (JAGSNPHARM) shares.

In which sector do JAGSONPAL PHARMACEUTICALS LTD. (JAGSNPHARM) belong?

JAGSONPAL PHARMACEUTICALS LTD. (JAGSNPHARM) belongs to Pharma.

About JAGSNPHARM

Today's live share price for JAGSONPAL PHARMACEUTICALS LTD. is NSE: ₹ 334.60, BSE: ₹ 335.40 with a current market capitalization of .

Promoted by J S Kochhar in 1978, Jagsonpal Pharmaceuticals is engaged in the manufacture and marketing bulk drugs and pharmaceuticals at its plant at Faridabad in Haryana. The company has adopted the strategy of clubbing all its products in seven groups for effective marketing and reducing costs. Simultaneously it has geared up to set up an ultra modern multi-purpose basic drugs and formulation plant through its subsidiary, Jagsonpal Exports India Pvt Ltd. The company has a strategic alliance with Fidia Spa, Italy; and B Spofola, Czechoslovakia; to manufacture sophisticated drugs in India. It has tied up with another Israel-based company, Makhteshim Chemical Works, for acquiring the marketing rights of an anti-oxidant product. In 1994, the company has also promoted Aresco Financial Services, a new financial company. The Company's R&D activities have resulted in manufacturing process upgradation, improving packaging, and cost containment. It's R&D activities are geared towards development of new product technologies which can be commercialised in future. It has tied up with Lycored Natural Products Industries (LNP) of Israel, to launch a completely natural Lycopene bioactive product, Lycored, in India and SouthEast Asia. In the fiscal 2001, the company's sales grew by 15% to Rs 136.52 crore and the profit at the net level was up 8% to Rs 10.15 crore. This was achieved against heavy odds, such as, sluggish market trends, lower growth rate of the industry and severe competition from drug majors. However the company has introduced various measures to counter the above factors so as to achieve continued growth and opportunity.

Read more

Enjoy Zero Brokerage on Equity Delivery

Join our 1 Cr+ happy customers